Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | SGK1 | O00141 | 8/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20699358 | 0.92 | ESR1 (0.36) | ESR1ESR2GSK3BGSK3ACDK2 | |
| SCHEMBL30161875 | 0.92 | ESR1 (0.36) | ESR1ESR2GSK3BGSK3ACDK2 | |
| Trifluoroacetic Acid SCHEMBL29607460 | 0.83 | SGK1 (0.40) | ESR1ESR2GSK3BGSK3ACDK2 | |
| SCHEMBL20699371 | 0.80 | IDO1 (0.38) | GSK3BGSK3ACDK2PIK3CDPIM1 | |
| SCHEMBL30161563 | 0.80 | IDO1 (0.38) | GSK3BGSK3ACDK2PIK3CDPIM1 | |
| SCHEMBL20699365 | 0.79 | JAK3 (0.39) | — | |
| SCHEMBL20711756 | 0.77 | SGK1 (0.33) | ESR1ESR2GSK3BGSK3ACDK2 | |
| Trifluoroacetic Acid SCHEMBL29607590 | 0.76 | NAMPT (0.33) | ESR1ESR2CDK2SGK1IDO1 | |
| SCHEMBL20715202 | 0.76 | ESR1 (0.34) | ESR1ESR2GSK3BGSK3APIK3CA | |
| SCHEMBL17667703 | 0.74 | GSK3B (0.37) | ESR1ESR2GSK3BGSK3ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | ESR1 4593/4885ESR2 4477/4885GSK3B 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.